Heart Transplantation In Patients With Prior Malignancy: A Systematic Review From A Cardiologic Viewpoint | 22654
Journal of Cancer Science & Therapy
Like us on:
Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
A history of malignancy can be considered as a contraindication for heart transplantation in patients with end-stage heart
failure. A systematic search of the available literature about this theme resulted in some older case reports (n=3) and
small series. More recent series are larger (n=10), have a specific design or rely on nationwide databases (n=2). All reports are
retrospective in nature. Entirely pediatric series are excluded. The preoperative profile of the patients include demographics,
time interval between malignancy and transplantation (if available), indication of transplantation and co-morbid conditions.
Postoperative results include hospital mortality, long-term survival, recurrence of malignancy, infection and rejection rate.
Findings: 1) 10 to 27% of cancer survivors suffer from chemotherapy-related cardiomyopathy. Moreover, two series show that
the number of surviving cancer patients, needing transplantation is increasing; chemotherapy related end-stage heart failure
almost doubled as indication for transplantation between the periods 2000-2004 and 2004-2008. 2) Hospital mortality varied
between 0-10% in small series and seems comparable to patients without malignancy. 3) The same is true for 5-year survival,
being 55-75%. The disease free interval between malignancy and transplantation has an important effect on postoperative
survival and on recurrence rate of cancer: 5-year survival decreases from 80% to 55% if the interval decreases from 5 to
1 year. Recurrence rate of cancer increases from 6% to 63%. Although the published series are not comparable, it can be
concluded that transplantation in patients with prior malignancy can be justified when the interval between malignancy and
transplantation exceeds 5 years.
Wilhelm P Mistiaen graduated as MD at the University of Antwerp in 1984. In 1994, he completed a surgical training and registered as surgeon. He completed his
first PhD in 1999 and a second one in 2009 at the same university. Currently, he is Lecturer and Associate Professor of Anatomy and of Pathology at the University
of Antwerp/Artesis-Plantijn University College.The focus of interest is complications after aortic valve replacement. Another focus is heart disease in patients with
(prior) malignancy. Several manuscripts appeared on these topics. He is a regular reviewer for the European Journal of Cancer Prevention.
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals